Figure 4. Whole-body weight (left) and fat change (middle) with continued drug administration following the GTT (right) Packed cell volume (PCV) in whole blood from ob/ob mice treated with vehicle, rosiglitazone or ML244.

Figure 4

Whole-body weight (left) and fat change (middle) with continued drug administration following the GTT (right) Packed cell volume (PCV) in whole blood from ob/ob mice treated with vehicle, rosiglitazone or ML244. Error bars are S.E.M; *p<0.05, **p<0.01, ***p<0.001. n.s.; not significant.

From: Potent Anti-Diabetic Actions of a Novel Non-Agonist PPARγ Ligand that Blocks Cdk5-Mediated Phosphorylation

Cover of Probe Reports from the NIH Molecular Libraries Program
Probe Reports from the NIH Molecular Libraries Program [Internet].
Copyright Notice

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.